Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics Inc (DE:0K4)
FRANKFURT:0K4
Holding DE:0K4?
Track your performance easily
0K4 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€13.20 - €32.78
Previous Close€30.88
Volume0.00
Average Volume (3M)N/A
Market Cap
€2.13B
Enterprise Value€1.49B
Total Cash (Recent Filing)$717.25M
Total Debt (Recent Filing)$35.73M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Mar 13, 2025EPS Estimate
-€1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding69,799,148
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.85
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.48
Forecast
1Y Price Target
€47.05Price Target Upside55.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Akero Therapeutics News
PremiumCompany Announcements
Akero Therapeutics Advances in MASH Treatment Trials
PremiumPre-Earnings
Is AKRO a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAkero announced the initiation of SYNCHRONY Outcomes, a Phase 3 trial assessing efruxifermin in MASH patients with compensated cirrhosis, fibrosis stage 4.
Drug DevelopmentEfruxifermin continues to be one of the most exciting MASH drug candidates in development from conversations and polling of physicians.
Financial HealthAkero reported Q2 2024 earnings, finishing the period with $848.3M in cash, cash equivalents, and short/long-term marketable securities, which is expected to fund operations into the second half of 2027.
Bears Say
Clinical ResultsThe Ph2b SYMMETRY trial results showed clinical failure of EFX versus placebo in fibrosis improvement.
Clinical TrialsA higher rate of discontinuations at Week 96 in the SYMMETRY trial compared to the HARMONY trial is expected due to more advanced enrolled patients.
Operational RisksKey risks to the rating and price target include unforeseen safety or tolerability issues and the inability to sufficiently fund operations.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.27% Insiders
25.43% Mutual Funds
13.59% Other Institutional Investors
44.69% Public Companies and
Individual Investors
0K4 FAQ
What was Akero Therapeutics Inc’s price range in the past 12 months?
Akero Therapeutics Inc lowest stock price was €13.20 and its highest was €32.78 in the past 12 months.
What is Akero Therapeutics Inc’s market cap?
Currently, no data Available
When is Akero Therapeutics Inc’s upcoming earnings report date?
Akero Therapeutics Inc’s upcoming earnings report date is Mar 13, 2025 which is in 119 days.
How were Akero Therapeutics Inc’s earnings last quarter?
Akero Therapeutics Inc released its earnings results on Nov 08, 2024. The company reported -€0.986 earnings per share for the quarter, missing the consensus estimate of -€0.825 by -€0.161.
Is Akero Therapeutics Inc overvalued?
According to Wall Street analysts Akero Therapeutics Inc’s price is currently Undervalued.
Does Akero Therapeutics Inc pay dividends?
Akero Therapeutics Inc does not currently pay dividends.
What is Akero Therapeutics Inc’s EPS estimate?
Akero Therapeutics Inc’s EPS estimate is -€1.1.
How many shares outstanding does Akero Therapeutics Inc have?
Akero Therapeutics Inc has 69,799,150 shares outstanding.
What happened to Akero Therapeutics Inc’s price movement after its last earnings report?
Akero Therapeutics Inc reported an EPS of -€0.986 in its last earnings report, missing expectations of -€0.825. Following the earnings report the stock price went down -1.83%.
Which hedge fund is a major shareholder of Akero Therapeutics Inc?
Among the largest hedge funds holding Akero Therapeutics Inc’s share is Perceptive Advisors LLC. It holds Akero Therapeutics Inc’s shares valued at 35M.
---
Akero Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€47.05 (55.96% Upside)
€47.05 (55.96% Upside)
Blogger Sentiment
Bearish
DE:0K4 Sentiment 100%
Sector Average 73%
Sector Average 73%
Insider Transactions
Sold Shares
Worth $107.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.09%
12-Months-Change
Fundamentals
Return on Equity
-35.90%
Trailing 12-Months
Asset Growth
28.68%
Trailing 12-Months
Company Description
Akero Therapeutics Inc
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
---
0K4 Stock 12 Month Forecast
Average Price Target
€47.05
▲(55.96% Upside)
Technical Analysis
Akero Therapeutics
―
Apellis Pharmaceuticals
―
FibroGen
―
Mirum Pharmaceuticals
―
Viking Therapeutics
―
Best Analysts Covering 0K4
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+5.47%
reiterated a buy rating 9 months ago
Copying Michael Yee's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +5.47% per trade.
---